Stock events for Journey Medical Corp. (DERM)
Journey Medical Corp.'s stock price has increased by 63.78% from February 21, 2025, to February 20, 2026, trading between $4.97 and $9.56 over the past 52 weeks. Key events include the release of Third Quarter 2025 financial results in November 2025, the publication of clinical trial results for Emrosi in the Journal of Drugs in Dermatology, a price target increase to $13.77, and the reporting of combined Emrosi Phase 3 clinical trial efficacy data analysis. Lake Street initiated coverage with a "Buy" recommendation in September 2025. As of March 7, 2026, the average recommendation is "Hold" with a 12-month target price of $12.1667.
Demand Seasonality affecting Journey Medical Corp.’s stock price
While specific details are limited, there is an indication of "stronger dermatology months," suggesting seasonal fluctuations in demand for dermatological products. The company's strategy to offset potential uncertainties from legacy products until Emrosi takes the lead also hints at varying demand across its portfolio.
Overview of Journey Medical Corp.’s business
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing pharmaceutical products for dermatological conditions in the United States. The company has a portfolio of FDA-approved prescription drugs, including Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, Emrosi, and Luxamend. The company also sells authorized generic products, including sulconazole nitrate cream and solution, and doxycycline hyclate tablets.
DERM’s Geographic footprint
Journey Medical Corporation is headquartered in Scottsdale, Arizona, and primarily focuses on selling and marketing its FDA-approved prescription pharmaceutical products for dermatological conditions within the United States.
DERM Corporate Image Assessment
Journey Medical's brand reputation has been positively influenced by the commercial launch and performance of Emrosi. The FDA approved Emrosi in November 2024, and it achieved over 10% share of new prescription demand among dermatology writers in its third month of promotion. Payer access for Emrosi increased from 30% to approximately 65% of commercial lives. Positive responses from physicians and patients have led to over 12,800 Emrosi prescriptions. Clinical trial results assessing Emrosi's impact on microbial flora were published in the Journal of Drugs in Dermatology. The company's management rang the Nasdaq closing bell in August 2025 to celebrate its 4-year anniversary as a public company and the commercial launch of Emrosi.
Ownership
Journey Medical Corp. has a mixed ownership structure, with approximately 40.62% held by institutional shareholders, 31.12% by insiders, and 28.26% by retail investors. Major institutional owners include Tang Capital Management Llc, Wasatch Advisors Inc, and Opaleye Management Inc. Claude Maraoui, President, CEO, and Director, owns the most shares among individual investors. Fortress Biotech Inc is the largest individual shareholder, owning 4.11 million shares, representing 15.15% of the company.
